Arcutis Biotherapeutics, Inc. officer Patrick Burnett filed a Form 144 notice of proposed sale of securities on November 2, 2026, disclosing plans to sell 943 shares of common stock on NASDAQ.

Key Highlights

  • Proposed sale: Patrick Burnett, an officer of Arcutis Biotherapeutics, Inc., intends to sell 943 shares of common stock with an aggregate market value of $30,047.19.
  • Source of shares: The 943 shares were acquired on November 1, 2026, through a restricted stock vesting from Arcutis Biotherapeutics.
  • Approximate sale date: The proposed sale is dated November 2, 2026, to be executed through Merrill Lynch in Columbus, Ohio.
  • Shares outstanding: According to the filing, there were 125,691,961 shares of common stock outstanding at the time of the notice.
  • Prior sales in past 3 months: Burnett sold 8,300 shares on August 11, 2026, for gross proceeds of $220,129.66; 6,700 shares on August 12, 2026, for $174,767.62; and 1,697 shares on August 19, 2026, for $45,819.

Arcutis Officer Burnett Discloses Proposed Common Stock Sale Following November Vesting

Patrick Burnett, identified as an officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), submitted a Form 144 notice dated November 2, 2026, disclosing a proposed sale of 943 shares of the company's common stock. According to the filing, the shares carry an aggregate market value of $30,047.19 and are to be sold through Merrill Lynch, located at 8890 Lyra Drive, 5th Floor, Columbus, Ohio 43240.

The filing indicates that the 943 shares subject to the proposed sale were acquired on November 1, 2026, through a restricted stock vesting transaction from Arcutis Biotherapeutics, with a payment date also listed as November 1, 2026. The nature of payment is listed as "NA" in the filing. The company's address is listed as 3027 Townsgate Rd Ste 300, Westlake Village, California 91361, and the SEC file number is 001-39186.

The filing also discloses Burnett's sales of Arcutis common stock during the prior three months. According to the notice, he sold 8,300 shares on August 11, 2026, generating gross proceeds of $220,129.66; 6,700 shares on August 12, 2026, for gross proceeds of $174,767.62; and 1,697 shares on August 19, 2026, for gross proceeds of $45,819. By signing the notice, Burnett represented that he does not know any material adverse information regarding the current and prospective operations of Arcutis that has not been publicly disclosed.

What Was Disclosed

Arcutis Biotherapeutics officer Patrick Burnett filed a Form 144 on November 2, 2026, disclosing a proposed sale of 943 shares of common stock valued at $30,047.19, acquired through a restricted stock vesting on November 1, 2026, along with three prior sales totaling 16,697 shares since August 2026.